Cyanotech Corporation Insider Trading

Cyanotech Corporation (NASDAQ: CYAN) director Michael A. Davis has acquired additional shares in the company, as per a recent SEC filing.

Transactions Details

The transactions occurred on September 23 and 24, with Davis purchasing 10,000 shares of Cyanotech’s common stock totaling $7,500, at prices ranging from $0.73 to $0.77 per share.

These acquisitions were part of a pre-arranged trading plan (10b5-1(c)) adopted on March 6, 2024, allowing insiders to schedule trades ahead of time, which serves as a defense against claims of non-public information trading.

Increased Holdings

Davis, a company director and ten-percent owner, has notably enhanced his direct holdings. After these recent transactions, he now indirectly owns 1,440,440 shares through the Michael Arlen Davis Revocable Trust.

Company Overview

Cyanotech, incorporated in Nevada and based in Hawaii, specializes in medicinal chemicals and botanical products. The company operates under the trading symbol CYAN from its Kailua-Kona, HI facility.

Investors tend to monitor insider trading as it can indicate company performance and insider confidence. While insider purchases suggest optimism, they do not guarantee specific stock outcomes.

The filing was executed by Laura L. Taylor via Power of Attorney on September 25, 2024.

InvestingPro Insights

Davis’s recent insider purchase coincides with a positive analyst outlook for the company, highlighted by the InvestingPro Tips. Analysts anticipate sales growth this year, supporting Davis’s expanded stake.

Cyanotech’s stock has seen a significant increase of 164.15% over the past three months, likely affecting Davis’s decision-making under the 10b5-1(c) plan.

Market Capitalization and Financials

Cyanotech has a market cap of $5 million, suggesting growth potential. As of Q1 2025, the company reported revenue growth of 10.25% over the past year and a gross profit margin of 25.58%.

While Cyanotech operates with moderate debt and has not achieved profitability recently, analysts expect it to turn profitable this year. The combination of this anticipated profitability and recent insider buying indicates a promising outlook for the company’s financial future. However, potential investors should note the absence of dividends, which may deter income-focused options.

Further Insights

For additional details about Cyanotech and market position insights, visit InvestingPro Tips.

This article was generated with AI assistance and reviewed by an editor. For further information, refer to our T&C.